Nasal Polyps Treatment Market Overview:
The global nasal polyps treatment market size was valued at $2,482.7 million in 2020, and is projected to reach $4,243.9 million by 2030 registering a CAGR of 5.60% from 2021 to 2030. Nasal polyps are soft, painless, and noncancerous growths on lining of nasal passages or sinuses. It results from chronic inflammation and are associated with asthma, recurring infection, allergies, drug sensitivity, or certain immune disorders. Nasal polyp treatments such as medications are used to shrink or eliminate nasal polyps, as well as surgery is sometimes needed to remove them.
Increase in geriatric population suffering from chronic rhinosinusitis with nasal polyps (CRSwNP), rapid utilization of minimally-invasive surgeries by otorhinolaryngologist surgeons, and rich pipeline of nasal polyps treatment options with growing research activities are some factors that drive growth of the nasal polyps treatment market. However, high cost and complications associated with sinus surgeries such as excessive bleeding, cerebrospinal fluid leak, visual disturbances, postoperative scarring, and inflammation hamper growth of the market. In addition, adverse reactions associated with steroid therapies such as weight gain, loss of bone mineral density, and cataract formation in eyes restraint growth of the market. On the contrary, availability of key technologies such as nasal endoscopy and computerized tomography has created fresh opportunities for growth within the global nasal polyps treatment market.
The outbreak of COVID-19 has disrupted workflows in the health care sector around the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of health care. However, there is positive impact of COVID-19 on the nasal polyps treatment market as demand for antibiotics increases due to symptoms associated with nasal polyps such as loss in sense of smell and taste, feeling of congestion or stuffiness, and, in rare cases, difficulty breathing. COVID-19 may affect upper or lower respiratory tract while in sinus infection, inflamed cavities around nasal passages can be observed. In addition, sinus infection and COVID-19 share similar symptoms, it is important to know the difference. As a result, in the ongoing pandemic, the nasal polyps treatment market is expected to grow, owing to increase in demand for diagnostic tests and antibiotics. Hence, the outbreak of COVID-19 has positively impacted the nasal polyps treatment market.
Nasal polyps treatment market segmentation
The global nasal polyps treatment market is segmented on the basis of type of treatment, route of administration, distribution channel, and region to provide a detailed assessment of the market. By type of treatment, it is bifurcated into corticosteroids, antibiotics, leukotriene inhibitors, and others. Others include antihistamines. By route of administration, it is segmented into oral, nasal, and others. Others include injectable and topical. On the basis of distribution channel, it is categorized into hospitals pharmacies, retail pharmacies, and online pharmacies. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Segment Review
On the basis of type of treatment, the corticosteroids segment dominated the global market in 2020, and is expected to remain dominant throughout the forecast period, owing to factors such as increase in demand for corticosteroids treatment and its availability in various dosage forms such as injections, intranasal sprays, and drops according to the need of patients.
By Type Of Treatment
Corticosteroids segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.
On the basis of route of administration, the nasal segment dominated the global market in 2020 and is anticipated to continue this trend during the forecast period. This is attributed to the fact that nasal delivery route is an encouraging way of delivering drugs into the body as compared to other drug delivery routes such as oral and others. This delivery route helps drugs to directly reach at the site of infection or allergic areas. Administration of drugs via nose provides a rapid action of drug in the body of patients.
By Route Of Administration
Nasal segment is projected as one of the most lucrative segment.
On the basis distribution channel, the retail pharmacies segment held the largest market share in 2020, and is expected to remain dominant throughout the forecast period, owing to increase in preference by population, as it is the oldest and most conventional medium distributing nasal polyps treatment products such as corticosteroids, antibiotics, and leukotriene inhibitors to consumers, owing to its large chain of distribution network of pharmacies stores and availability of these products at retail stores at discounted price.
Snapshot of the Asia-Pacific Nasal Polyps Treatment Market
Asia-Pacific offers profitable opportunities for key players operating in the nasal polyps treatment market, which is expected to encourage fastest growth rate during the forecast period, owing to growth in healthcare infrastructure, increase in prevalence of nasal polyps and its associated disorders such as asthma, sinusitis, and rise in disposable incomes, well-established presence of domestic companies, and aging population in the region.
By Region
North America is expected to experience growth at the highest rate, registering a CAGR of 4.90 % during the forecast period.
The key nasal polyps treatment market players profiled in the report include AstraZeneca plc., F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Intersect ENT Inc., Merck & Co Inc., Novartis International AG, OptiNose US, Regeneron Pharmaceuticals Inc., Sanofi S.A, and Teva Pharmaceutical Industries Ltd.
Key Benefits For Stakeholders
- The study provides an in-depth analysis of the global nasal polyps treatment market along with the current trends and future estimations to explain the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the nasal polyps treatment market growth is provided in the report.
- Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing nasal polyps treatment market opportunities.
- Extensive analysis of the key segments of the industry helps to understand the application and products of nasal polyps treatment used across the globe.
- Key market players and their strategies have been analyzed to understand the competitive outlook of the nasal polyps treatment market.
Key Market Segments
By Type of Treatment
- Corticosteroids
- Antibiotics
- Leukotriene Inhibitors
- Others
By Route of Administration
- Oral
- Nasal
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Nasal Polyps Treatment Market Report Highlights
| Aspects | Details |
 By TYPE OF TREATMENT |
|
 By ROUTE OF ADMINISTRATION |
|
 By DISTRIBUTION CHANNEL |
|
 By Region |
|
 Key Market Players | Sanofi S.A., ASTRAZENECA PLC, F. Hoffmann-La Roche AG, MERCK & CO., INC., GLAXOSMITHKLINE PLC, Intersect ENT, Optinose Inc., Novartis International AG, TEVA PHARMACEUTICAL INDUSTRIES LIMITED, Regeneron Pharmaceuticals, Inc. |
Analyst Review
Nasal polyps is a non-cancerous growth that forms inside the nose. It is usually a painless condition. Large growths can lead to breathing problems and loss of sense of smell. Nasal polyp is mostly caused due to collection of fluids within the nose and continue to swell forming a polyp. Nasal polyps treatments include surgical treatment and non-surgical treatment such as oral, nasal corticosteroids, antibodies, and leukotriene inhibitors.
Increase in prevalence of chronic rhinosinusitis with nasal polyps (CRSwNP) along with rise in geriatric population, rapid utilization of minimally-invasive surgeries by otorhinolaryngologist surgeons, and huge product pipeline of nasal polyps treatment with growing research activities are some factors that boost growth of the market. Furthermore, technological improvements in nasal polyps treatment is expected to create a lucrative opportunity for the market growth. However, high cost and complications associated with sinus surgeries and adverse reactions associated with steroid therapies are some factors expected to hinder growth of the market.
The corticosteroids segment is expected to remain dominant during the forecast period, owing to increase in demand for corticosteroids treatment and its availability in various dosage forms such as injections, intranasal sprays, and drops according to the need of the patients. Moreover, North America are expected to offer lucrative opportunities to the market during the forecast period, owing to presence of major key players in the countries like the U.S. In addition, presence of a large population with nasal polyps, increase in incidences of CRSwNP, surge in number of sinus surgeries, and rapid adoption of technologically-advanced products such as sinus implants in the region.
The total market value of nasal polyps treatment market is $4,243.9 million in 2020.
The forcast period for nasal polyps treatment market is 2021 to 2030
The market value of nasal polyps treatment market in 2021 is $2,592.00 million.
The base year is 2020 in root canal sealer market
Top companies such as Sanofi S.A, GlaxosmithKline Plc., F. Hoffmann La Roche AG, Merck & Co. Inc., Teva Pharmaceuticals, Novartis International AG held a high market position in 2020.
corticosteroids segment is the most influencing segment owing to increase in the demand for corticosteroids treatment and its availability in various dosage forms like injections, intranasal sprays, and drops according to the need of the patient.
increase in prevalence of chronic rhinosinusitis with nasal polyps (CRSwNP) along with rise in geriatric population, rapid utilization of minimally-invasive surgeries by otorhinolaryngologist surgeons, and huge product pipeline of nasal polyps treatment with growing research activities are some factors which boost growth of the market. Furthermore, technological improvement in nasal polyps treatment expected to create a lucrative opportunity for market growth
Asia-Pacific is expected to experience the highest growth rate during the forecast period, owing to growing healthcare infrastructure, increasing prevalence of nasal polyps and its associated disorders such as asthma, sinusitis, rising disposable incomes, well-established presence of domestic companies, and aging population in the region.
Nasal polyps are a chronic inflammatory condition of the nose and paranasal sinuses
Nasal polyps treatment such as oral and nasal medications are used to shrink or eliminate nasal polyps.
Loading Table Of Content...
